AstraZeneca Migrates to SAP Cloud ERP Private and Explores Business AI, Deepening 20-Year Partnership
Global biopharmaceutical giant AstraZeneca announced its migration to SAP Cloud ERP Private via the RISE with SAP program and is evaluating SAP's business AI capabilities, including Joule, to streamline operations and accelerate decision-making.
German software company SAP SE (NYSE: SAP) announced on November 10, 2026, that global biopharmaceutical company AstraZeneca is migrating to SAP Cloud ERP Private through the "RISE with SAP" journey, expanding the two companies' 20-year relationship. This full-estate migration aims to simplify and standardize AstraZeneca's technology landscape, creating a more agile and resilient digital foundation.
As part of its "Axial Business Transformation Programme," AstraZeneca is moving from legacy SAP ERP Central Component environments to SAP Cloud ERP Private to support more standardized ways of working, harmonized data, and connected processes across the enterprise. Chris Taylor, Chief Information Officer at AstraZeneca, stated that this next chapter is about more than modernizing technology; it is about simplifying operations to unlock greater value from AI, enabling the company to turn insight into action faster.
Regarding AI applications, AstraZeneca is exploring a range of business AI capabilities from SAP, including the Industry AI portfolio, the Joule solution, and agentic use cases across finance, supply chain, and manufacturing. These capabilities have the potential to enhance productivity, strengthen data quality and governance, and enable faster decision-making. Additionally, the SAP Business Data Cloud solution can support AstraZeneca in building a clean data core, while the SAP Green Ledger solution helps embed sustainability considerations into core business processes.